Literature DB >> 11696640

Preclinical evaluation of the penciclovir analog 9-(4-[(18)F]fluoro-3-hydroxymethylbutyl)guanine for in vivo measurement of suicide gene expression with PET.

M M Alauddin1, A Shahinian, E M Gordon, J R Bading, P S Conti.   

Abstract

UNLABELLED: The gene for herpes simplex virus thymidine kinase (HSV-tk) is widely used as a suicide gene in experimental gene therapy of cancer. 9-(4-Fluoro-3-hydroxymethylbutyl)guanine (FHBG) is an antiviral nucleoside analog that is rapidly phosphorylated by viral thymidine kinase but is a poor substrate for mammalian thymidine kinase. Recently, FHBG labeled in the 4-fluoro position with (18)F has shown promise relative to other similar compounds for imaging in vivo expression of HSV-tk using PET. In this study, we evaluated the uptake of [(18)F]FHBG in vitro and in vivo using transduced and wild-type human colon cancer cells (HT-29). We also imaged [(18)F]FHBG and measured the radioactivity concentrations of circulating [(18)F]FHBG and its metabolites in monkeys.
METHODS: Sterile, pyrogen-free [(18)F]FHBG was produced routinely in good yields. Cells were transduced with the retroviral vector G1Tk1SvNa containing HSV-tk gene. In vitro uptake studies were performed by incubating cells with [(18)F]FHBG at 37 degrees C for 1 and 5 h. Biodistribution studies were performed at 2 and 5 h after injection in nude mice bearing tumors grown from wild-type or transduced cells. Sequential, whole-body PET scans of cynomolgus monkeys were obtained over a period of >2 h after intravenous injection of [(18)F]FHBG. Arterial plasma samples obtained from monkeys 15-120 min after intravenous injection were subjected to acid extraction, and the acid-soluble fractions were analyzed by high-performance liquid chromatography.
RESULTS: In vitro studies showed 31 and 71 (P < 0.001) times higher uptake of the probe at 1 and 5 h, respectively, in transduced cells compared with nontransduced cells. In vivo studies in mice showed that tumor uptake of the radiotracer was 4-fold (P < 0.05) and 13-fold (P < 0.001) higher at 2 and 5 h, respectively, in tumors grown from transduced cells compared with control cells. Transduced tumor-to-normal tissue ratios ranged from 2 to 25 at 2 h and from 2 to 22 at 5 h. Recirculating labeled metabolites had only a minor effect on the biodistribution of radiolabel from [(18)F]FHBG in monkeys.
CONCLUSION: These results indicate that [(18)F]FHBG may yield high-contrast PET images of HSV-tk expression in tumors and, therefore, it is a very promising radiotracer for monitoring of gene therapy of cancer with PET.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11696640

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  16 in total

1.  Noninvasive imaging of protein-protein interactions in living animals.

Authors:  Gary D Luker; Vijay Sharma; Christina M Pica; Julie L Dahlheimer; Wei Li; Joseph Ochesky; Christine E Ryan; Helen Piwnica-Worms; David Piwnica-Worms
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-07       Impact factor: 11.205

2.  Structure-guided engineering of human thymidine kinase 2 as a positron emission tomography reporter gene for enhanced phosphorylation of non-natural thymidine analog reporter probe.

Authors:  Dean O Campbell; Shahriar S Yaghoubi; Ying Su; Jason T Lee; Martin S Auerbach; Harvey Herschman; Nagichettiar Satyamurthy; Johannes Czernin; Arnon Lavie; Caius G Radu
Journal:  J Biol Chem       Date:  2011-11-09       Impact factor: 5.157

Review 3.  Imaging stem cells implanted in infarcted myocardium.

Authors:  Rong Zhou; Paul D Acton; Victor A Ferrari
Journal:  J Am Coll Cardiol       Date:  2006-11-01       Impact factor: 24.094

4.  Comparison of [14C]FMAU, [3H]FEAU, [14C]FIAU, and [3H]PCV for monitoring reporter gene expression of wild type and mutant herpes simplex virus type 1 thymidine kinase in cell culture.

Authors:  Keon Wook Kang; Jung-Joon Min; Xiaoyuan Chen; Sanjiv S Gambhir
Journal:  Mol Imaging Biol       Date:  2005 Jul-Aug       Impact factor: 3.488

5.  Non-invasive imaging of cardiac transgene expression with PET: comparison of the human sodium/iodide symporter gene and HSV1-tk as the reporter gene.

Authors:  Masao Miyagawa; Martina Anton; Bettina Wagner; Roland Haubner; Michael Souvatzoglou; Bernd Gansbacher; Markus Schwaiger; Frank M Bengel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-09       Impact factor: 9.236

6.  Different strategies for reducing intestinal background radioactivity associated with imaging HSV1-tk expression using established radionucleoside probes.

Authors:  Alessandro Ruggiero; Peter Brader; Inna Serganova; Pat Zanzonico; Shangde Cai; Neil S Lipman; Hedvig Hricak; Ronald G Blasberg
Journal:  Mol Imaging       Date:  2010-02       Impact factor: 4.488

7.  Non-invasive in vivo imaging with radiolabelled FIAU for monitoring cancer gene therapy using herpes simplex virus type 1 thymidine kinase and ganciclovir.

Authors:  Win-Ping Deng; Wen K Yang; Wen-Fu Lai; Ren-Shyan Liu; Jeng-Jong Hwang; Den-Mei Yang; Ying-Kai Fu; Hsin-Ell Wang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-09-25       Impact factor: 9.236

Review 8.  PET-based molecular imaging in neuroscience.

Authors:  A H Jacobs; H Li; A Winkeler; R Hilker; C Knoess; A Rüger; N Galldiks; B Schaller; J Sobesky; L Kracht; P Monfared; M Klein; S Vollmar; B Bauer; R Wagner; R Graf; K Wienhard; K Herholz; W D Heiss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-23       Impact factor: 9.236

9.  Positron emission tomography (PET) imaging with (18)F-based radiotracers.

Authors:  Mian M Alauddin
Journal:  Am J Nucl Med Mol Imaging       Date:  2011-12-15

10.  In vivo evaluation of 2'-deoxy-2'-[(18)F]fluoro-5-iodo-1-beta-D-arabinofuranosyluracil ([18F]FIAU) and 2'-deoxy-2'-[18F]fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil ([18F]FEAU) as markers for suicide gene expression.

Authors:  Mian M Alauddin; Antranic Shahinian; Ryan Park; Michel Tohme; John D Fissekis; Peter S Conti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-06       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.